Evommune (EVMN) Accounts Payables (2024 - 2026)

Evommune (EVMN) has reported Accounts Payables for 3 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables changed N/A year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (changed N/A YoY), while the FY2025 annual figure was $7.8 million, down 6.15% from the prior year.
• Accounts Payables fell to $4.0 million in Q1 2026 per EVMN's latest filing, from $7.8 million in the prior quarter.
• Across five years, Accounts Payables topped out at $8.3 million in Q4 2024 and bottomed at $3.6 million in Q3 2025.
• Historically, Accounts Payables has averaged $5.9 million across 3 years, with a median of $5.9 million in 2025.
• On a YoY basis, Accounts Payables climbed as much as 6.15% in 2025 and fell as far as 6.15% in 2025.
• Evommune's Accounts Payables stood at $8.3 million in 2024, then decreased by 6.15% to $7.8 million in 2025, then tumbled by 47.85% to $4.0 million in 2026.
• Business Quant data shows EVMN's Accounts Payables at $4.0 million in Q1 2026, $7.8 million in Q4 2025, and $3.6 million in Q3 2025.